Recent clinical trials of Novo Nordisk’s blockbuster GLP-1 drug semaglutide for Alzheimer’s disease may have failed to show ...

Investing.com -- Moody’s Ratings has affirmed Eli Lilly and Company’s Aa3 senior unsecured notes ratings and long-term issuer rating while revising the outlook to positive from stable, the rating ...

Alzheimer's trials testing Novo Nordisk’s blockbuster GLP-1 drug semaglutide, despite their failure, underscore a shift to ...

Dec 12 (Reuters) - Alzheimer's trials testing Novo Nordisk’s blockbuster GLP-1 drug semaglutide, despite their failure, ...

Experts at a roundtable in Boston, Massachusetts, on November 3, 2025, discussed improving early Alzheimer disease diagnosis, addressing workforce and equity gaps, and expanding access to new ...

Clinicians and health system leaders met in Portland, Oregon, on October 21, 2025, to discuss the evolving options for treating Alzheimer disease and multiple sclerosis.

Bristol Myers Squibb moves forward with its ADEPT-2 study on Cobenfy, delaying data to next year but boosting investor ...

China approves 19 innovative drugs for commercial health insurance, opening new market opportunities for global and local ...

IBM will reportedly pay $11B for the data streaming company. Lilly, Pfizer, J&J in China’s private insurance catalog. White ...

Mounjaro and Pfizer’s ($PFE) cancer drugs were added to China’s state-run health insurance scheme, according to the country’s ...

Pfizer (PFE), and Johnson & Johnson (JNJ) secured spots on China's first innovative drug catalog for private insurance, ...